fsd pharma inc., through its subsidiary, fv pharma inc., produces medical cannabis in canada. the company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for central nervous system disorders and autoimmune diseases of the skin, gi tract, and musculoskeletal system, such as chronic pain. fsd pharma inc. has strategic alliance agreements with scicann therapeutics inc., canntab therapeutics, and solarvest bioenergy inc. the company was founded in 1998 and is headquartered in toronto, canada.
![Quantum Biopharma logo](/files/LOGO/1771885-HUGE.png)
Company profile
Ticker
QNTM, HUGE
Exchange
Website
CEO
Raza Bokhari
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
QNTM stock data
Latest filings (excl ownership)
6-K/A
Condensed consolidated interim financial statements
19 Aug 24
6-K
Current report (foreign)
15 Aug 24
6-K
Current report (foreign)
15 Aug 24
6-K/A
Current report (foreign) (amended)
14 Aug 24
6-K
Condensed consolidated interim financial statements
14 Aug 24
6-K
FSD Pharma Announces Share Consolidation and Name Change
12 Aug 24
6-K
Current report (foreign)
9 Aug 24
6-K
FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders
29 Jul 24
6-K
Annual General and Special Meeting of the Shareholders to Be Held on Management Information Circular
8 Jul 24
6-K
Amended and Restated Material Change Report
8 Jul 24
Financial summary
Quarter (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2024
13F holders | Current |
---|---|
Total holders | 16 |
Opened positions | 15 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 157.23 mm |
Total shares | 14.77 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Durkacz Anthony | 13.70 mm | $0.00 |
AdvisorShares Investments | 555.18 k | $75.51 mm |
Renaissance Technologies | 305.30 k | $49.46 mm |
Jane Street | 104.10 k | $17.50 mm |
UBS UBS | 31.05 k | $5.03 mm |
Susquehanna International | 27.95 k | $4.48 mm |
HRT Financial | 16.13 k | $2.00 k |
Group One Trading | 12.86 k | $2.06 mm |
BMO Bank of Montreal | 11.16 k | $2.41 mm |
RY Royal Bank of Canada | 1.37 k | $0.00 |
News
Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
16 Aug 24
'Trump Endorsing Florida Marijuana Legalization Initiative Would 'Guarantee Victory,' Top Ally Roger Stone Says' - Marijuana Moment
13 Aug 24
Why Rumble Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
13 Aug 24
FSD Pharma Rebrands As Quantum BioPharma: Major Share Consolidation Announced
12 Aug 24
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
12 Aug 24
Press releases
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month - Created by a World-Class Pharmaceutical Research & Development Team
9 Aug 24
FSD Pharma Enters Into an Exclusive Option Agreement With the University of Southern California To Evaluate Novel Dietary Supplement Technology for unbuzzd(TM) and Other Business Applications
13 Jun 24
FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
4 Jun 24
FSD Pharma, Inc. Wins Petition to Confirm Arbitration Awards Entered Against Dr. Raza Bokhari Totaling Over $3 Million CAD, Plus Interest
31 May 24
FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
28 May 24